Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 8;44(7):708-715.
doi: 10.1097/INF.0000000000004821.

Impact of Universal PCV10 Vaccination on Invasive Pneumococcal Disease in Croatian Children

Iva Butić  1   2 , Goran Tešović  1   3 , Kristian Bodulić  1 , Sandra Lucić  1 , Irena Groš  1 , Marija Gužvinec  1 , Arjana Tambić Andrašević  1   2 ; Study group for invasive isolates of Croatian Committee for Antibiotic Resistance Surveillance
Collaborators, Affiliations

Impact of Universal PCV10 Vaccination on Invasive Pneumococcal Disease in Croatian Children

Iva Butić et al. Pediatr Infect Dis J. .

Abstract

Introduction: Despite the worldwide usage of pneumococcal conjugated vaccines (PCVs), Streptococcus pneumoniae remains a major cause of morbidity and mortality among children. This study evaluated the effects of universal PCV10 vaccination on incidence, serodistribution and antimicrobial resistance among S. pneumoniae strains causing invasive pneumococcal disease (IPD) in Croatian children.

Methods: The study analyzed consecutive, nonredundant invasive S. pneumoniae isolates obtained from children up to 18 years of age, collected through a network of microbiologic laboratories in Croatia from 2005 to 2023. Serotyping was performed by the capsular swelling method. In vitro susceptibility testing was performed according to the EUCAST guidelines.

Results: During the 19-year study period, 601 invasive S. pneumoniae strains were analyzed. This included 543 isolates in the pre-PCV10 period and 58 isolates in the post-PCV10 period. Bacteremic pneumonia and serotype 3 were significantly more common in the post-PCV10 period. A significant reduction in the incidence of IPD caused by PCV10 serotypes was observed in the post-PCV10 period in all age groups, with the highest reduction of 81.0% in children <5 years. The cumulative incidence of isolates susceptible, increased exposure to penicillin and isolates resistant to macrolides increased significantly slower in the post-PCV10 period.

Conclusions: The introduction of PCV10 significantly changed the IPD epidemiology in Croatian children. The prevalence of PCV10 isolates decreased, with the current serodistribution suggesting the need for novel pneumococcal conjugates. Given the relatively low prevalence of isolates with PCV10 and PCV13 serotypes, PCV15 and PCV20 may be the most suitable candidates for future use.

Keywords: PCV10 impact; antibiotic resistance; children; invasive pneumococcal disease; serotypes.

PubMed Disclaimer

Conflict of interest statement

I.B. reports a relationship with Pfizer Inc. and Merck Sharp & Dohme Corp that includes speaker and lecture fees. G.T. reports financial support, administrative support, article publishing charges and equipment, medications, or supplies, provided by Pfizer Inc.; financial support, administrative support and equipment, medications, or supplies, provided by Merck Sharp & Dohme Corp.; and a relationship with Pfizer Inc and Merck Sharp & Dohme Corp that includes speaker and lecture fees. A.T.A. financial support, administrative support, or supplies, provided by Pfizer Inc.; a relationship with Pfizer Inc. and Merck Sharp & Dohme Corp that includes speaker and lecture fees. The other authors have no funding or conflicts of interest to disclose.

References

    1. WHO Publications. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper—February 2019. Wkly Epidemiol Rep. 2019;94:85–104.
    1. VIEW-hub report: global vaccine introduction and implementation, 2024. Available at: https://view-hub.org/resources . Accessed September 4, 2024.
    1. Savulescu C, Krizova P, Valentiner-Branth P, et al.; SpIDnet VE Study Group. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40:3963–3974.
    1. Guzman-Holst A, de Barros E, Rubio P, et al. Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020. Hum Vaccin Immunother. 2022;18:1879578.
    1. Agudelo CI, Castañeda-Orjuela C, Brandileone MCC, et al.; SIREVA Working Group. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study. Lancet Infect Dis. 2021;21:405–417.

MeSH terms

Substances

LinkOut - more resources